Zelira Therapeutics Limited (ASX:ZLD)

Zelira Therapeutics Limited has released its Preliminary Final Report for the year ended 30 June 2025. The company reported a loss of $3,849,672 for the year, which is a significant decrease from the previous year's loss of $36,739,759. The loss per share decreased to 33.52 cents from 322.27 cents. Revenue from the sale of goods fell drastically from $94,952 in 2024 to $656 in 2025, with sales of Zenivol® and HOPE® in Australia contributing $140, and sales of oral care products and other items in the US contributing the remaining amount. Despite a reduced gross profit, the company benefited from a research and development incentive of $1,152,779. Operating cash flow was negative at $4,906,854 due to high payments to suppliers and employees, along with significant research and development expenses. The company's strategic financial moves included the issuance of convertible notes and entering into related party loans to improve liquidity.